What question did this study set out to answer?

To evaluate the efficacy and safety of a cladribine-based conditioning regimen for allo-HSCT in children with R/R AML.

March 7, 2026Frontiers in MedicineOpen Access

Efficacy and safety of a new cladribine-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with relapsed or refractory acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Authors

Single-center study demonstrates promising safety and efficacy of cladribine conditioning for allo-HSCT in children, suggesting potential benefits.

To evaluate the efficacy and safety of a cladribine-based conditioning regimen for allo-HSCT in children with R/R AML.
Retrospective analysis of clinical data from 16 children who underwent allo-HSCT with cladribine conditioning.
Assessment of hematopoietic reconstruction and regimen-related toxicity.
Evaluation of GVHD incidence and overall survival, disease-free survival, and non-relapse mortality.
Hematopoietic reconstruction achieved in all patients; 81.25% were MRD negative pre-transplant.
1-year overall survival rate was 87.5% and disease-free survival rate was 87.4%.
The incidence of grade I/II regimen-related toxicity was 31.3%, with no cases of grade III/IV observed.

Pei et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Single-center study demonstrates promising safety and efficacy of cladribine conditioning for allo-HSCT in children, suggesting potential benefits.